Last $23.90 USD
Change Today +1.01 / 4.41%
Volume 175.5K
HPTX On Other Exchanges
As of 8:10 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

hyperion therapeutics inc (HPTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/28/14 - $32.98
52 Week Low
11/7/13 - $18.97
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

hyperion therapeutics inc (HPTX) Related Bloomberg News

View More Bloomberg News

hyperion therapeutics inc (HPTX) Related Businessweek News

No Related Businessweek News Found

hyperion therapeutics inc (HPTX) Details

Hyperion Therapeutics, Inc., a commercial biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. The company’s products include RAVICTI, which is used as a nitrogen-binding agent for chronic management of adult and pediatric urea cycle disorder (UCD) patients greater than two years of age, who cannot be managed by dietary protein restriction and/or amino acid supplementation alone; and BUPHENYL, an FDA-approved therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California.

54 Employees
Last Reported Date: 03/7/14
Founded in 2006

hyperion therapeutics inc (HPTX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $575.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $347.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $375.0K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $347.0K
Chief Legal & Compliance Officer, Senior Vice...
Total Annual Compensation: $195.9K
Compensation as of Fiscal Year 2013.

hyperion therapeutics inc (HPTX) Key Developments

Hyperion Therapeutics, Inc. Presents at Leerink Rare Disease Roundtable, Oct-01-2014 09:15 AM

Hyperion Therapeutics, Inc. Presents at Leerink Rare Disease Roundtable, Oct-01-2014 09:15 AM. Venue: Le Parker Meridian Hotel, New York, New York, United States.

Hyperion Therapeutics, Inc. - Special Call

To discuss the terminating the development of DiaPep277 for newly diagnosed Type 1 diabetes

Hyperion Therapeutics, Inc. Elects Theodore "Ted" Schroeder to its Board of Directors

Effective August 11, 2014, the Board of Directors of Hyperion Therapeutics, Inc. elected Theodore "Ted" Schroeder to serve as a Class III director of the company, filling a vacancy created by the resignation of David Gryska from the Board in March 2014. As a Class III director, Mr. Schroeder will serve until his re-election at the annual meeting of stockholders to be held in 2015 or until his successor is elected and qualified. At this time, Mr. Schroeder has not been appointed to a committee of the Board. Mr. Schroeder has over two decades of experience in the life sciences industry. Most recently, he was the founder of Cadence Pharmaceuticals, Inc., serving as its president and chief executive officer from inception until its acquisition by Mallinckrodt Pharmaceuticals.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HPTX:US $23.90 USD +1.01

HPTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HPTX.
View Industry Companies

Industry Analysis


Industry Average

Valuation HPTX Industry Range
Price/Earnings 25.5x
Price/Sales 5.1x
Price/Book 3.1x
Price/Cash Flow 19.6x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HYPERION THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at